CLINICAL TRIAL / NCT04625270

Inclusion Criteria: - Histologically proven LGSOC (ovarian, peritoneal) - Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease. - Measurable disease according to RECIST 1.1 - An Eastern Cooperative Group (ECOG) performance status ≤ 1. - Adequate organ function - Adequate recovery from toxicities related to prior treatments - Agreement to use highly effective method of contraceptive, if necessary Exclusion Criteria: - Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy - Co-existing high-grade ovarian cancer or another histology - History of prior malignancy with recurrence <3 years from the time of enrollment - Major surgery within 4 weeks - Symptomatic brain metastases requiring steroids or other interventions - Known SARS-Cov2 infection (clinical symptoms) ≤28 days prior to first dose of study therapy - For subjects with prior MEK exposure, Grade 4 toxicity deemed related to the MEK inhibitor - Active skin disorder that has required systemic therapy within the past year - History of rhabdomyolysis - Concurrent ocular disorders - Concurrent heart disease or severe obstructive pulmonary disease - Subjects with the inability to swallow oral medications